Vijaya Diagnostics Q2 FY27 Revenue Up 26.7% to ₹255 Crore; EBITDA Grows 37.8%
Vijaya Diagnostic Centre reported Q2 FY27 revenue of ₹255 crore, up 26.7% YoY, driven by 16.5% volume growth. EBITDA rose 37.8% to ₹113 crore, with margins expanding to 44.1%. The company plans significant CAPEX of ₹155-160 crore for network expansion, including new hubs and spokes, and is acquiring Arya Wellness Centre in Guwahati.
The announcement includes robust financial performance, significant network expansion plans, and a strategic acquisition, all of which are material to the company's future growth and investor outlook.
The company reported strong year-on-year growth in revenue and profits, along with improved EBITDA margins, and provided positive outlook and expansion plans.
Vijaya Diagnostic Centre Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The company reported a consolidated revenue of approximately ₹255 crore for the current quarter, marking a strong year-on-year growth of 26.7%. This growth was primarily driven by a 16.5% increase in test volumes and a favorable change in test mix, along with revisions in CGHS tariffs.
EBITDA for the quarter stood at approximately ₹113 crore, a 37.8% increase year-on-year, with EBITDA margins improving by 350 basis points to 44.1%, attributed to operating leverage. Profit after tax (PAT) for the quarter was ₹59 crore, up 37.4% year-on-year, with a PAT margin of 23.3%.
For the half-year ended September 2026, consolidated revenue grew by 24.8% to ₹486 crore, while EBITDA increased by 36% to ₹211 crore, maintaining a strong EBITDA margin of 43.4%. PAT for the half-year was ₹113 crore with a PAT margin of 23.1%.
The company is expanding its network, with plans to commission three more hub centers in the second half of FY '27 and three additional hubs in Q1 FY '28, involving a CAPEX of approximately ₹155-160 crore. Additionally, a new central laboratory at Panjagutta, land acquisition in Kadapa, and relocation/upgradation of hubs in Pune are planned. The acquisition of Arya Wellness Centre in Guwahati, Assam, is expected to be completed in the next two months, marking the company's entry into the Northeast region.
Management indicated confidence in achieving at least a 20% growth rate for the current financial year and a mid-teen growth of above 15% for a sustainable long-term revenue guidance. The company expects EBITDA margins to remain above 42% for FY '27.
What to do with a filing like this
Vijaya Diagnostic Centre Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Vijaya Diagnostic Centre Limited. Read the original for the full detail.